You are here: Industry Insights > Psoriasis

News List

InnoCare Announces First Patient Dosed in the Phase III Registrational Trial of ICP-488 for the Treatment of Psoriasis in China PharmaSources
March 20, 2025
InnoCare announced the first patient dosing in the Phase III trial of ICP - 488 for psoriasis. It showed good results in Phase II, aiming to meet unmet needs.
Data of InnoCare's ICP-488 for the Treatment of Psoriasis Presented at Late Breaking Oral Presentation of 2025 AAD PharmaSources
March 11, 2025
InnoCare Pharma; TYK2 inhibitor ICP - 488; psoriasis; 2025 AAD Annual Meeting; clinical data
InnoCare Announces the Completion of Patient Enrollment in the Phase II Clinical Trial of ICP-488 for the Treatment of Psoriasis PharmaSources
May 16, 2024
InnoCare announced the completion of patient enrollment for the phase II clinical trial of ICP-488, a TYK2 (tyrosine kinase 2) JH2 allosteric inhibitor, for the treatment of psoriasis.
MC2 Therapeutics and Huadong Announce License, Development and Commercialization Agreement for Wynzora® Cream in Greater China B3C newswire
November 06, 2023
today an agreement under which Huadong has been granted exclusive rights in Greater China (mainland China, Hong Kong, Macau and Taiwan) to develop and commercialize MC2’s drug.
InnoCare Announces First Psoriasis Patient Dosed in Clinical Trial of TYK2 Allosteric Inhibitor ICP-488 in China PharmaSources
July 05, 2023
On July 5, 2023,InnoCare Pharma announced the first psoriasis patient has been dosed in clinical trial of the Company’s TYK2 JH2 allosteric inhibitor ICP-488 in China.
Lipidor Announces Enrolment of First Patients in a Phase III Study on AKP02 for Treatment of Psoriasis prnasia
January 29, 2022
Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) today reports that the first patients have been enrolled in a Phase III clinical study using AKP02 cutaneous spray...
Specialist-Led Model of Care Can Improve CVD Prevention in Psoriasis drugs.com
January 19, 2022
Dermatologists and patients with psoriatic disease have a positive view of a specialist-led model of care to improve cardiovascular...
FDA Accepts Arcutis Biotherapeutics’ New Drug Application for Roflumilast Cream for Adults and Adolescents with Plaque Psoriasis Drugs
December 27, 2021
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the U.S. Food and Drug Administration’s (FDA)...
COVID-19 Severity Does Not Differ for Patients With Skin Conditions Drugs
December 16, 2021
For patients with psoriasis, vitiligo, atopic dermatitis (AD), and chronic urticaria (CU), COVID-19 severity does not differ, but treatment of COVID-19 may affect the course of skin disease...
Psoriasis Ups Risk for Vascular Disease, Venous Thromboembolism Drugs
December 08, 2021
There is an increased risk for venous thromboembolism (VTE) and peripheral vascular disease (PVD) among patients with psoriatic disease, according to a review published online Dec. 1 in JAMA Dermatology.

Previous page 1 2 3 4 5 6 7 8 9 10 Next page